Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DARE-204 and DARE-214 are long-acting injectable formulations of etonogestrel being developed by Daré Bioscience for contraception. DARE-204 is designed to provide protection for 6 months, while DARE-214 is designed for 12 months. These products utilize Orbis Biosciences' precision particle fabrication technology to achieve sustained release of the active progestogen. Etonogestrel acts as a progesterone receptor agonist, inhibiting ovulation and providing contraceptive efficacy. The program aims to provide the first FDA-approved injectable contraceptives with 6- and 12-month durations, offering improved ease of use and a predictable return to fertility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DARE-204 + DARE-214.